Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from ONE-YEAR RESULTS OF GEOGRAPHIC ATROPHY PATIENTS WITH PREEXISTING nAMD TREATED WITH BOTH ANTI-VEGF THERAPY AND PEGCETACOPLAN. Local targets link to admitted publications; unresolved targets remain external evidence.
Therapeutic innovations for geographic atrophy: a promising horizon
10.1016/j.coph.2024.102484 · 2024 · External reference
GATHER2 trial investigators. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
10.1016/s0140-6736(23)01583-0 · 2023 · External reference
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial
10.1038/s41433-023-02497-w · 2023 · External reference
Annual prevalence of geographic atrophy and wet age-related macular degeneration among Medicare Advantage enrollees in a US health plan
2025 · External reference
Results of patients with neovascular age-related macular degeneration managed by a treat-extend-stop protocol without recurrence
10.1007/s00417-021-05283-0 · 2021 · External reference
Growth rate of geographic atrophy secondary to age-related macular degeneration: a meta-analysis of natural history studies and implications for designing future trials
10.1159/000510507 · 2021 · External reference
Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL Study)
10.1016/j.ophtha.2019.08.023 · 2020 · External reference
Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials
10.1016/j.ophtha.2016.03.045 · 2016 · External reference
Pegcetacoplan treatment for geographic atrophy in age-related macular degeneration over 36 months: data from OAKS, DERBY, and GALE
10.1016/j.ajo.2025.04.016 · 2025 · External reference
Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration
10.1016/j.ophtha.2017.11.036 · 2018 · External reference
OAKS and DERBY study investigators. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
10.1016/s0140-6736(23)01520-9 · 2023 · External reference
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results
10.1016/j.ophtha.2012.03.053 · 2012 · External reference
